Skip to content
Search

Latest Stories

RPS Scotland appoints Laura Wilson as Director

The Royal Pharmaceutical Society (RPS) has appointed Laura Wilson as Director for Scotland commencing 23rd January 2023.

Laura, is currently Policy and Practice Lead for RPS in Scotland. She is accountable for bringing national RPS policy to life for members in Scotland, while contributing to the GB wide professional leadership agenda.


She will work closely with the Scottish Pharmacy Board, senior NHS officials and other key stakeholders across the breadth of the pharmacy profession and beyond to ensure pharmacy is on the forefront of healthcare in Scotland.

She joins the existing team of RPS Country Directors, which includes Elen Jones, Director for Wales and James Davies, Director for England and will report directly to the Chief Executive.

Laura Wilson said: “I am delighted to be appointed Director for Scotland having worked as part of the RPS Scotland team as the policy and practice lead.  It will be an honour to continue the fantastic work started by former Director Clare Morrison to bring Pharmacy 2030, our vision for pharmacy in Scotland in the future, to life and supporting pharmacy teams to deliver person centred care.

"With exciting times ahead for pharmacy, it will be an honour to continue to work with Board members, staff, stakeholders, and members to deliver the vision and mission of RPS and ensure a vibrant future for the pharmacy profession in Scotland.”

RPS CEO Paul Bennett commented: "After a rigorous and open selection process, Laura’s appointment as the Director for Scotland is especially pleasing to announce as she will be known by many in her previous RPS Scotland role where she has worked collaboratively and in partnership with a wide range of stakeholders to make a significant impact on the pharmacy policy landscape. She will also be well known to many across Scotland for her drive and passion for pharmacy having held roles in NHS Greater Glasgow and Clyde as Advanced Pharmacist in Addictions, as a Teacher Practitioner at Strathclyde University, as a Community Pharmacist and as a Hospital Pharmacist. I look forward to welcoming Laura to the team in her new position."

Scottish Pharmacy Board Chair, Andrew Carruthers added: "Laura has extensive clinical experience, across multiple sectors, as well as experience of developing and writing pharmacy policy to the benefit of our members and the public. Having worked very closely with Laura in her current role, I know that she has the passion and knowledge to continue to drive improvements in pharmacy practice across Scotland and GB. I, and the Scottish Pharmacy Board, very much look forward to working with Laura in her new role."

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less